Harding Loevner
Harding Loevner Global Small Companies Equity
Global Small-cap
Dec 2024 → Mar 2026
Our archive holds 3 letters from this strategy, behind 6 investment theses and positions in 23 companies. Every quote below is copied verbatim from the letter it came from.
3 letters in 3 years — follow all of Harding Loevner for every strategy.
Also held
Its investment theses
- Simulations PlusDec 2025Simulations Plus provides drug-development modeling software with strong regulatory and market tailwinds supporting long-term growth.
- SysmexDec 2025Sysmex is a diagnostics leader with high switching costs and a large installed base positioning it for mid- to upper-single-digit revenue growth.
- Carl Zeiss MeditecSep 2025Carl Zeiss Meditec is positioned to benefit from long-term growth in the vision-care market despite short-term demand softness, with 51% of its sales from recurring revenue and a strong competitive advantage.
- SysmexSep 2025Sysmex is a high-quality global leader in diagnostic analyzers with 78% recurring sales, now attractively valued due to recent share-price weakness stemming from short-term growth challenges.
- LEM HoldingDec 2024LEM Holdings is expanding its market presence in EVs and traditional industries while leveraging its in-house designed ASICs for competitive advantage.
- ShiftDec 2024Shift is Japan’s leading outsourced software testing provider, positioned to thrive amid a shortage of IT engineers by training workers from other industries to meet increasing tech demands.